Cellectis S.A. (NASDAQ:CLLS) Short Interest Update

Cellectis S.A. (NASDAQ:CLLS) was the target of a large growth in short interest in September. As of September 15th, there was short interest totaling 488,061 shares, a growth of 68.5% from the August 31st total of 289,689 shares. Based on an average daily trading volume, of 207,376 shares, the short-interest ratio is currently 2.4 days. Currently, 0.6% of the shares of the stock are short sold.

Cellectis Trading Up 2.0%

NASDAQ:CLLS traded up $0.03 during midday trading on Wednesday, hitting $1.50. The stock had a trading volume of 6,198 shares, compared to its average volume of 52,967. The stock has a 50-day moving average of $2.70 and a 200 day moving average of $3.16. The company has a market capitalization of $150.51 million, a price-to-earnings ratio of -2.31 and a beta of 2.92. Cellectis has a one year low of $1.25 and a one year high of $5.48. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The business had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million.

Analysts Set New Price Targets

Several analysts have recently issued reports on CLLS shares. Robert W. Baird decreased their target price on shares of Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 15th. Weiss Ratings lowered Cellectis from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Barclays lowered Cellectis from an “overweight” rating to an “underweight” rating and lowered their price objective for the company from $9.00 to $1.30 in a research note on Wednesday, September 16th. Citizens Jmp reaffirmed a “market perform” rating on shares of Cellectis in a research note on Tuesday, September 15th. Finally, Wells Fargo & Company reduced their price target on Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $5.46.

Institutional Trading of Cellectis

A hedge fund recently bought a new stake in Cellectis stock. Lido Advisors LLC acquired a new position in Cellectis S.A. (NASDAQ:CLLS) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.